ArticleThe breast journal2026
Integrating Serum Lipid Biomarkers Into Machine Learning for the Differential Diagnosis of Breast Nodules.
Article in The breast journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Serum Lipid Biomarkers Into Machine Learning for the Differential Diagnosis of Breast Nodules.The breast journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo develop and validate an interpretable machine learning (ML) model for predicting malignant risk in patients with breast nodules using serum lipid biomarkers.
methodsThis retrospective study included 899 patients with breast nodules (236 malignant) admitted between March 2022 and December 2024. Patients were randomly assigned to a training cohort (n = 630) and an internal validation cohort (n = 269) at a 7:3 ratio. Baseline clinical and laboratory data were collected upon admission. Following feature selection via LASSO regression, the predictive performance of 8 ML algorithms was evaluated and compared using receiver operating characteristic (ROC) curves. The optimal model's performance was further corroborated using an independent temporal validation cohort of 190 patients (admitted Jan-Aug 2025). Model interpretability was addressed using SHapley Additive exPlanations (SHAP).
resultsNine key predictors were identified from 20 candidates by Lasso regression and clinical expertise. The random forest (RF) model outperformed other algorithms, achieving areas under the curve (AUC) values of 0.789, 0.782, and 0.825 for the training, internal validation, and temporal validation cohorts, respectively. Hosmer-Lemeshow tests (p > 0.05) indicated high calibration between the predicted and observed risks. SHAP importance analysis revealed Fer, age, and CEA to be the top three predictive factors.
conclusionThe RF model based on serum lipid biomarkers serves as a robust, noninvasive tool for assessing breast cancer risk, showing significant potential for clinical decision support in screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.